Liver cancer staging in India follows two systems that work side by side: the Barcelona Clinic Liver Cancer (BCLC) system and the AJCC TNM system. This guide explains what each stage of liver cancer means, how stage is decided, what treatment looks like stage by stage, and how care is delivered at tertiary centres in Delhi, Gurgaon and Noida. It is written for patients and families who have just heard the words hepatocellular carcinoma and want a clear picture before the next appointment [1][3].
What Liver Cancer Staging Means
Staging describes how far a liver cancer has grown inside the liver, whether it has invaded blood vessels, and whether it has spread outside the liver. For hepatocellular carcinoma (HCC), the most common primary liver cancer in India, staging also accounts for how well the underlying liver is working, because most HCC arises on a background of cirrhosis. Two patients with the same 3 cm tumour can end up with very different treatment plans once liver function and performance status are added to the picture. This is why liver cancer staging is unusual compared with staging of breast, colon or lung cancer [1][2].
Why Staging Matters in Hepatocellular Carcinoma
In HCC, stage is the single strongest driver of whether treatment is curative, locoregional or systemic. A BCLC 0 tumour in a well-compensated cirrhotic liver is potentially curable with ablation or resection; the same tumour burden in a Child-Pugh C patient with poor performance status is treated as terminal disease with best supportive care. The stage label is not a statistic; it is a gate that opens or closes specific treatment options at Indian tumour boards [3][6].
The BCLC Staging System Explained
The Barcelona Clinic Liver Cancer system groups patients into five stages: 0 (very early), A (early), B (intermediate), C (advanced) and D (terminal). Stage assignment uses tumour number and size, vascular invasion, spread outside the liver, the Child-Pugh liver function score, and ECOG performance status. BCLC is the system most used in day-to-day clinical decision making at leading cancer centres in the region, ILBS and a leading cancer centre because it links each stage directly to a recommended treatment pathway rather than leaving the choice open [3][5].
AJCC TNM Staging for Liver Cancer
The AJCC 8th edition TNM system is used for pathology reporting after liver resection and for cancer registries. T categories are based on tumour size, number and vascular invasion: T1a is a solitary tumour up to 2 cm; T1b is solitary over 2 cm without vascular invasion; T2 is solitary with vascular invasion or multiple tumours none over 5 cm; T3 is multiple with at least one over 5 cm; T4 involves a major branch of portal or hepatic vein, direct invasion of adjacent organs other than the gallbladder, or perforation of visceral peritoneum. N1 indicates regional node involvement and M1 indicates distant metastasis [4].
Okuda and CLIP Systems in Indian Practice
Two older liver cancer staging systems still surface in Indian hospital records. The Okuda system combines tumour size with ascites, serum albumin and bilirubin. The CLIP (Cancer of the Liver Italian Program) score adds alpha-fetoprotein and portal vein thrombosis. a tertiary cancer centre and a tertiary cancer centre publications typically report BCLC as the primary system and TNM for surgical cases, while CLIP and Okuda may appear in older case series or registry work where long follow-up data is being compared [6].
Child-Pugh Score and Its Role in Liver Cancer Staging
The Child-Pugh score combines bilirubin, albumin, INR, ascites and hepatic encephalopathy to grade underlying liver function as class A, B or C. A Child-Pugh A patient has preserved liver reserve and is a candidate for the full range of HCC therapies including resection, transplantation, ablation, TACE and systemic therapy. Child-Pugh B narrows options, and Child-Pugh C generally rules out liver resection and most systemic agents because the liver cannot tolerate further injury. Every BCLC stage call checks Child-Pugh first [3][6].
MELD Score and Liver Transplant Eligibility
The MELD (Model for End-Stage Liver Disease) score uses bilirubin, creatinine, INR and sodium to predict short-term mortality in cirrhosis. For HCC patients being considered for liver transplantation at Indian centres such as ILBS, leading cancer centres and AIG, MELD drives waiting-list priority alongside HCC exception points for tumours within Milan criteria. MELD does not replace BCLC; it sits beside it as the transplant-specific assessment [5][6].
Stage 0: Very Early Liver Cancer
BCLC 0 (very early) HCC is defined as a single tumour up to 2 cm, with no vascular invasion, in a Child-Pugh A patient with ECOG performance status 0. Most BCLC 0 lesions are found on six-monthly surveillance ultrasound in patients with known cirrhosis or chronic hepatitis B, not because of symptoms. Curative treatment with ablation, resection or transplantation is the standard at this stage, and five-year survival in carefully selected series is favourable [3][7].
Stage A: Early Liver Cancer
BCLC A (early) disease includes a solitary HCC of any size or up to three nodules each up to 3 cm, in a Child-Pugh A or B patient with preserved performance status. Treatment is still curative in intent. Resection is preferred for single tumours in patients with no clinically significant portal hypertension. Transplantation within Milan criteria is the only option that treats both the cancer and the underlying cirrhosis, and is offered at several NCR living-donor programmes [5][6].
Stage B: Intermediate Liver Cancer
BCLC B (intermediate) HCC is multinodular disease without vascular invasion or extrahepatic spread, in patients with Child-Pugh A or B liver function and good performance status. Standard of care is transarterial chemoembolisation (TACE), using either conventional lipiodol-doxorubicin TACE or drug-eluting bead TACE. Patients who become refractory to TACE are increasingly moved to systemic therapy earlier rather than repeating futile embolisation cycles, in line with updated ESMO and NCCN guidance [3][5].
Stage C: Advanced Liver Cancer
BCLC C (advanced) HCC involves portal or hepatic vein invasion, regional lymph node spread, or distant metastases, with ECOG performance status of 1 or 2. Patients may present with worsening jaundice, ascites, bone pain from skeletal metastases, or breathlessness from lung metastases. First-line systemic therapy for Child-Pugh A patients now centres on atezolizumab plus bevacizumab, based on the IMbrave150 trial which showed superior overall survival versus sorafenib [3][5].
Stage D: Terminal Liver Cancer
BCLC D (terminal) is defined more by liver failure and poor performance status than by tumour burden alone. It covers Child-Pugh C patients or those with ECOG 3 to 4. Focus shifts to symptom control, palliative care, nutrition, psychosocial support and management of hepatic decompensation. Ascites drainage, encephalopathy management and pain control are prioritised over anti-tumour therapy. Decisions are made jointly with the patient, family and palliative care team [5].
Symptoms of Liver Cancer by Stage
Very early and early stage HCC is often silent. Intermediate stage tumours may cause a dull ache in the right upper abdomen, early satiety, unintended weight loss or low-grade fever. Advanced disease brings worsening jaundice, ascites, bone pain, breathlessness and encephalopathy when liver function drops. Because cirrhosis produces its own symptoms at the same time, it can be hard to separate tumour symptoms from background liver disease, which is one reason surveillance imaging matters so much in HCC [1][2].
Risk Factors That Influence Stage at Diagnosis
Chronic hepatitis B is the single largest driver of HCC in India, followed by hepatitis C, alcohol-related cirrhosis, and non-alcoholic fatty liver disease linked to diabetes and obesity. Aflatoxin exposure from poorly stored grains contributes in some regions. Patients with known cirrhosis who stay in surveillance programmes are far more likely to be diagnosed at BCLC 0 or A. Those diagnosed after symptoms appear are usually already at BCLC B or C, which is a consistent finding in Indian tertiary centre audits [8][9].
Surveillance Programmes and Early-Stage Detection
Six-monthly abdominal ultrasound with alpha-fetoprotein testing is the standard HCC surveillance protocol for patients with cirrhosis, chronic hepatitis B carriers with high-risk features, and selected hepatitis C patients after sustained virological response. In Indian tertiary centres, a majority of first HCC presentations are still at intermediate or advanced stages because surveillance uptake lags behind countries with mature programmes. Closing that gap is the single highest-impact intervention for stage-at-diagnosis in HCC [7][10].
Diagnostic Workup for Staging Liver Cancer
A full HCC staging workup usually includes complete blood count, liver function tests, coagulation profile, renal function and alpha-fetoprotein; hepatitis B surface antigen, hepatitis C antibody and HIV serology; multiphase contrast-enhanced CT of the abdomen or, preferably, dynamic contrast MRI with a hepatobiliary agent; chest CT for staging; and bone scan or PET-CT when clinically indicated. Biopsy is reserved for lesions in a non-cirrhotic liver, atypical imaging or when clinical trial enrolment requires tissue confirmation [1][4].
Imaging Criteria (LI-RADS and AASLD) for HCC
HCC is unusual among solid tumours because a tissue biopsy is not always required. In a cirrhotic liver, a lesion that shows arterial phase hyperenhancement followed by washout in the portal venous or delayed phase can be called HCC on imaging alone, using LI-RADS or AASLD criteria. This is why every Indian HCC workup leans on dynamic contrast MRI or multiphase CT interpreted by radiologists familiar with hepatobiliary imaging protocols [3][5].
Role of Alpha-Fetoprotein in Staging
Alpha-fetoprotein (AFP) is a tumour marker that supports HCC diagnosis, surveillance and treatment monitoring. AFP over 400 ng/mL in a cirrhotic patient with a suspicious liver lesion is highly suggestive of HCC. Persistent AFP elevation after curative treatment raises the suspicion of recurrence. AFP at or above 400 ng/mL is also one of the entry criteria for second-line ramucirumab in advanced disease. It does not replace imaging, but it is part of every HCC stage assessment in Indian practice [3][5].
Treatment of Stage 0 and Stage A: Curative Intent
For BCLC 0 and A HCC, curative options include surgical resection, radiofrequency or microwave ablation, and liver transplantation. Ablation is often preferred for subcapsular or central lesions up to 2 cm in well-compensated cirrhosis. Resection works best for solitary tumours with preserved liver function and no clinically significant portal hypertension. The choice between these three depends less on tumour size alone and more on the joint assessment of tumour, liver function and transplant candidacy [3][6].
Liver Transplantation and Milan Criteria
Liver transplantation within Milan criteria (one lesion up to 5 cm or up to three lesions each up to 3 cm, no vascular invasion, no extrahepatic spread) is the only HCC treatment that addresses both the cancer and the underlying cirrhosis. In India, deceased-donor allocation is limited, and living-donor liver transplantation at centres such as ILBS, leading cancer centres and AIG defines practical access. Extended criteria beyond Milan are used at selected centres with careful case selection [5][6].
TACE and TARE for Stage B Liver Cancer
Transarterial chemoembolisation remains the default for BCLC B HCC with preserved liver function, and is also used as a bridging therapy before transplantation. Transarterial radioembolisation (TARE) with yttrium-90 is an option at selected Indian interventional radiology centres, particularly for larger unilobar tumours or portal vein tumour thrombus where conventional TACE is less suitable. The threshold to switch from repeat TACE to systemic therapy is lower now than it was five years ago [3][5].
Systemic Therapy for Stage C: IMbrave150 and HIMALAYA
First-line systemic therapy for advanced HCC in Child-Pugh A patients now centres on atezolizumab plus bevacizumab, based on the IMbrave150 trial which showed superior overall survival and progression-free survival versus sorafenib. Durvalumab plus tremelimumab (the STRIDE regimen, HIMALAYA trial) is an alternative for patients with varices or bleeding risk that contraindicates bevacizumab. Tyrosine kinase inhibitors including sorafenib and lenvatinib remain options where immunotherapy access is limited [3][5].
Second-Line Options for Advanced HCC
Second-line systemic options after progression on first-line therapy include regorafenib, cabozantinib, ramucirumab (for patients with AFP 400 ng/mL or higher), and nivolumab or pembrolizumab-based regimens where accessible. Sequencing decisions take into account Child-Pugh status at the time of progression, prior toxicity, AFP level and patient preference. At NCR tumour boards, second-line choices are reviewed jointly by medical oncology, hepatology and interventional radiology [3][5].
Palliative Care for Stage D Liver Cancer
BCLC D HCC care is led by the palliative care team in coordination with hepatology. Priorities include pain management, ascites drainage, encephalopathy treatment, nutrition support, infection prevention, and psychosocial support for patient and family. Anti-tumour therapy is generally withheld because the liver cannot tolerate further injury and performance status limits benefit. Early palliative care referral, including at diagnosis of advanced disease, improves symptom burden and quality of life [5].
Cost of Liver Cancer Treatment in Delhi, Gurgaon and Noida
Indicative 2025 to 2026 private-sector ranges in INR, drawn from published hospital tariffs, TPA rate cards and PMJAY package rates. Diagnostic workup with triple-phase CT or multiphase MRI, AFP, liver function panel, viral serology and guided biopsy: 25,000 to 70,000, with PET-CT adding 18,000 to 28,000. Radiofrequency or microwave ablation: 1.8 to 3.5 lakh. Hepatic resection: 4.5 to 9 lakh. Living-donor liver transplantation: 22 to 38 lakh at leading cancer centres in the region and ILBS. TACE: 1.2 to 2.2 lakh per sitting. Yttrium-90 TARE: 14 to 20 lakh per treatment. Atezolizumab plus bevacizumab: 3.5 to 5.5 lakh per cycle before patient-assistance discounts. Lenvatinib or sorafenib: 25,000 to 55,000 per month [11][12][13].
Clinical Trials Shaping Stage-Based Treatment
Recent and ongoing trials that shape how Indian oncologists think about HCC staging include IMbrave150 (atezolizumab plus bevacizumab), HIMALAYA (durvalumab plus tremelimumab STRIDE), LEAP-002 (lenvatinib plus pembrolizumab), CheckMate 9DW (nivolumab plus ipilimumab first line), EMERALD-1 (durvalumab plus bevacizumab added to TACE in intermediate stage), LEAP-012 (lenvatinib plus pembrolizumab added to TACE) and adjuvant IMbrave050 (atezolizumab plus bevacizumab after curative resection or ablation in high-risk patients). These trials are pushing immunotherapy earlier into the BCLC decision tree [3][5][15].
Frequently Asked Questions About Liver Cancer Stages
How is the stage of liver cancer decided in India? Staging follows both AJCC TNM and BCLC. BCLC is used more often in clinical decisions because it brings liver function, performance status and tumour burden together [3][6]. Can early stage liver cancer be cured? BCLC 0 and selected BCLC A patients can achieve long-term disease control with resection, ablation or transplantation [5][6]. What is the role of a liver transplant? Transplantation treats both the tumour and the diseased liver for patients meeting Milan or extended criteria [5]. When is immunotherapy used? Atezolizumab plus bevacizumab is first-line for advanced HCC in Child-Pugh A patients; durvalumab plus tremelimumab is an alternative where bevacizumab is contraindicated [3][5]. Is TACE still relevant? Yes, it remains the default for BCLC B disease and as a bridge to transplantation [5]. How are hepatitis B or C managed alongside cancer treatment? Antiviral therapy for HBV is continued to reduce reactivation; HCV is treated with direct-acting antivirals when timing allows [6][7]. What does follow-up look like after curative treatment? AFP and multiphase imaging every three to six months for two years, with lifelong hepatology follow-up [5][6]. What support is available for cost? PMJAY, CGHS, ECHS, state schemes, employer insurance and hospital corpus funds can cover parts of HCC treatment [13][14].
Sources and References
[1] National Cancer Institute, Adult Primary Liver Cancer Treatment (PDQ) Health Professional Version, 2025. cancer.gov/types/liver/hp/adult-liver-treatment-pdq. [2] NCI SEER, Cancer Stat Facts, Liver and Intrahepatic Bile Duct Cancer, 2025. seer.cancer.gov/statfacts/html/livibd.html. [3] ESMO Clinical Practice Guidelines, Hepatocellular Carcinoma, updated 2024. esmo.org/guidelines. [4] AJCC Cancer Staging Manual, 8th edition, Liver chapter. [5] NCCN Clinical Practice Guidelines in Oncology, Hepatobiliary Cancers, 2025. nccn.org/guidelines. [6] a tertiary cancer centre, Evidence Based Management of Cancers in India, HCC chapter. a tertiary cancer centre.gov.in. [7] WHO, Global Hepatitis Report 2024. who.int. [8] IARC GLOBOCAN 2022, India fact sheet, liver. gco.iarc.fr/today. [9] ICMR National Cancer Registry Programme Report, 2020 to 2024. ncdirindia.org. [10] a tertiary cancer centre New Delhi, HCC management protocol summaries. a tertiary cancer centre.edu. [11] NCI, Liver Cancer Treatment Options by Stage, 2025. cancer.gov. [12] IARC, Handbook on Primary Liver Cancer, 2024 update. iarc.who.int. [13] a tertiary cancer centre, Hospital-based Cancer Registry annual report, 2024. a tertiary cancer centre.gov.in. [14] WHO India, Noncommunicable Disease country profile 2024, liver section. who.int/india. [15] ESMO Open, Real-world outcomes of atezolizumab plus bevacizumab in HCC, 2024. esmoopen.com. [16] NCI PDQ, Childhood Liver Cancer Treatment, 2025. cancer.gov. [17] ICMR, Consensus Document for Management of Hepatocellular Carcinoma, 2023. main.icmr.nic.in.
Overview
Treatment Options